Back to Results
First PageMeta Content
Immunosuppressants / Medicine / Cytokines / Autoimmune diseases / Treatment of multiple sclerosis / Glatiramer acetate / Natalizumab / Fingolimod / Interferon beta-1a / Immunology / Immune system / Multiple sclerosis


Microsoft Word - Sanofi- 5.1 alemtuzumabPSD final.docx
Add to Reading List

Document Date: 2015-04-22 23:39:46

Open Document

File Size: 205,06 KB

Share Result on Facebook

City

Trial / Wollheim / /

Company

Sanofi-Aventis Australia Pty Ltd / New England Journal / Ford / SENTINEL / Multiple Sclerosis Collaborative Research Group / S508 New England Journal / PG / Neurology Meeting 2012 New England Journal / Genzyme Corporation / /

Continent

America / /

Country

United States / /

Currency

pence / /

Event

FDA Phase / /

Facility

Consumer Comments facility / /

IndustryTerm

treatment of multiple sclerosis / treatment of MS / magnetic resonance imaging / healthcare utilisation / magnetic resonance imaging outcomes / therapy for multiple sclerosis / /

MedicalCondition

MS Disease / organized multiple sclerosis / disease / MRI-monitored disease / cognitive impairment / remitting multiple sclerosis - MRI / multiple sclerosis O / early relapsing-remitting multiple sclerosis / pain / aggressive disease / active disease / progressive / chronic disease / fatigue / Relapsing-remitting multiple sclerosis / multiple sclerosis / MS / remitting multiple sclerosis / clinical and radiological disease / baseline disease / /

Organization

Congress / Poster E-002 European Committee for Treatment and Research / American Academy of Neurology / Abstract P491 European Committee for Treatment and Research / FDA / /

Position

physician / /

Product

Copaxone / Rebif / Avonex / CAMMS223 / Beta-1a / BG / /

ProvinceOrState

Mississippi / Georgia / /

PublishedMedium

The Lancet / New England Journal of Medicine / Archives of Neurology / /

Technology

magnetic resonance imaging / Trial ID Protocol / MRI / /

SocialTag